Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy.

ABSTRACT: Cancer immunotherapy has revolutionized treatment and led to an unprecedented wave of immuno-oncology research during the past two decades. In 2018, two pioneer immunotherapy innovators, Tasuku Honjo and James P. Allison, were awarded the Nobel Prize for their landmark cancer immunotherapy work regarding "cancer therapy by inhibition of negative immune regulation" -CTLA4 and PD-1 immune checkpoints. However, the challenge in the coming decade is to develop cancer immunotherapies that can more consistently treat various patients and cancer types. Overcoming this challenge requires a systemic understanding of the underlying interactions between immune cells, tumor cells, and immunotherapeutics. The role of aberrant glycosylation in this process, and how it influences tumor immunity and immun

SUBMITTER: Chiang AWT 

PROVIDER: S-EPMC8218521 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature